Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 5
2018 7
2019 8
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis.
Sidana S, et al. Mayo Clin Proc 2019. PMID 30718070
OBJECTIVE: To evaluate the prognostic impact of Holter findings in patients with light chain amyloidosis. PATIENTS AND METHODS: We evaluated 239 patients in whom light chain amyloidosis was diagnosed from January 1, 2010, through December 31, 2015, who underwent 24-hour Holter monitoring. ...
OBJECTIVE: To evaluate the prognostic impact of Holter findings in patients with light chain amyloidosis. PATIENTS AND METHODS: We ev …
Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis.
Sidana S, et al. Leukemia 2018. PMID 29483709 Free PMC article.
We evaluated the prognostic impact of clonal circulating plasma cells (cPCs) detected by six-color multi-parametric flow cytometry (MFC) in light chain (AL) amyloidosis at diagnosis. ...
We evaluated the prognostic impact of clonal circulating plasma cells (cPCs) detected by six-color multi-parametric flow cytometry (MFC) in …
Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).
Tandon N, et al. Am J Hematol 2018. Among authors: Sidana S. PMID 28960427 Free article.
Achievement of a normal FLC ratio (FLCr) following treatment indicates hematologic response and suggests better outcomes in light chain amyloidosis (AL). ...
Achievement of a normal FLC ratio (FLCr) following treatment indicates hematologic response and suggests better outcomes in light chain a
Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis.
Sidana S, et al. Bone Marrow Transplant 2018. PMID 29269795
There is limited data on the impact of melphalan in light chain (AL) amyloidosis, especially in the plerixafor era. We retrospectively evaluated stem cell mobilization in 610 patients with AL amyloidosis, of which 79 had prior exposure to melphalan, 167 to other chemotherapeutics, while 364 had no chemotherapy exposure. ...
There is limited data on the impact of melphalan in light chain (AL) amyloidosis, especially in the plerixafor era. We retrospectivel …
Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis.
Tandon N, et al. Amyloid 2017. Among authors: Sidana S. PMID 28699793
We analysed factors predicting early treatment failure (ETF), after first-line therapy for light-chain amyloidosis (AL). AL amyloidosis patients seen at Mayo Clinic within 90 days of diagnosis, from 2006 to 2015, excluding those who died within 3 months of initial therapy, were analysed retrospectively. ...
We analysed factors predicting early treatment failure (ETF), after first-line therapy for light-chain amyloidosis (AL). AL amyloi
Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis.
Tandon N, et al. Am J Hematol 2017. Among authors: Sidana S. PMID 28314084 Free article.
We analyzed the outcomes following initial relapse or refractory disease in systemic light chain amyloidosis (AL) and the impact of type of therapy employed.A total of 1327 patients with AL seen at Mayo Clinic within 90 days of diagnosis, between 2006 and 2015, were reviewed. ...
We analyzed the outcomes following initial relapse or refractory disease in systemic light chain amyloidosis (AL) and the impact of t …
17 results
Jump to page
Feedback